www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 23), pp: 16489-16500 Research Paper Targeting oncogenic Ras by the Clostridium perfringens toxin TpeL Björn Schorch1, Hannah Heni1, Nour-Imene Zahaf1, Tilman Brummer2,3,4, Marina Mione5,6, Gudula Schmidt1, Panagiotis Papatheodorou1,7,8 and Klaus Aktories1,4 1Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany 2Institut für Molekulare Medizin und Zellforschung, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany 3German Cancer Consortium (DKTK), Partner Site Freiburg, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany 4Centre for Biological Signalling Studies (BIOSS), Albert-Ludwigs-Universität Freiburg, Freiburg, Germany 5Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggestein-Leopoldshafen, Germany 6Present Address: Center for Integrative Biology, University of Trento, Trento, Italy 7Present Address: Institute of Pharmaceutical Biotechnology, University of Ulm, Ulm, Germany 8Present Address: Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany Correspondence to: Klaus Aktories, email:
[email protected] Keywords: Clostridium perfringens toxin; glycosylation; immunotoxins; paradoxical activation; Ras Received: April 04, 2017 Accepted: March 02, 2018 Published: March 27, 2018 Copyright: Schorch et al. This is an open-access article distributed under the terms of